Rare Cancer Recovery for Dual Primary Metastatic Endometrial and Ovarian Cancer

When Madam Ho Yee Mun, 62-year-old Malaysian, was first diagnosed in 2021, imaging revealed a large pelvic mass measuring approximately 13 × 9 × 9 cm, with internal solid components suspicious for ovarian malignancy. Further evaluation confirmed synchronous endometrioid adenocarcinoma of the endometrium (Stage 1B) and endometrioid adenocarcinoma of the ovary (Stage 1C1) and later metastasize to Lung as Stage 4. It is a Rare Cancer Recovery journey.

In October 2021 she underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO) followed by six cycles of chemotherapy between November 2021 and March 2022. Early follow-up imaging after treatment showed no evidence of local recurrence, and for some time her condition remained clinically stable.

However, in 2024 follow-up scans began to show signs of renewed disease activity. CT imaging demonstrated enlarging soft-tissue nodules in the pelvis and new lung nodules in both lungs. A restaging PET-CT performed in December 2024 confirmed active metastatic disease involving the lungs, pelvic lymph nodes, mesenteric deposits and abdominal wall lesions.

Despite these findings, the patient remained functionally well and physically active, continuing her normal daily life and work.

In January 2025, she began integrating ECCT into her treatment plan under clinical supervision alongside her ongoing oncology care. The intention was to provide additional biological support at a time when the disease had started to show systemic activity.

Over the months that followed, her overall condition remained stable. She continued working, maintained her strength, and reported no significant decline in daily function. Importantly, her follow-up imaging in July 2025 demonstrated that the disease had not progressed aggressively during this period. The lung nodules remained small, and while several soft-tissue lesions in the pelvis and abdominal wall were still visible, there was no evidence of widespread new metastatic spread or major organ compromise.

In addition to imaging findings, her tumour markers also showed encouraging changes over the course of treatment. Prior to starting ECCT in November 2024, her CA 19-9 level was elevated at 47.8 U/mL. After integrating ECCT into her care plan, the marker steadily declined and reached 5.3 U/mL by December 2025, returning to within the normal range. Other tumour markers remained stable or showed mild improvement during the same period. CA-125 decreased from 13.3 to 8.1 U/mL, and CA 15-3 remained low and stable. While tumour markers alone do not define disease status, the downward trend—particularly the significant reduction in CA 19-9—provides an additional indicator that the biological activity of the disease may have slowed during this time.

Another encouraging finding was the liver. Lesions previously seen in the liver remained consistent with benign cysts and showed no metabolic activity, confirming that the liver had not developed metastatic involvement.

Taken together, the imaging and clinical findings suggest a pattern of disease stabilization rather than continued progression. In advanced cancer, this shift can be an important outcome. Slowing tumor biological activity while preserving organ function and maintaining daily life can significantly change the overall trajectory of the disease.

Today, the patient continues her care with regular monitoring and individualized therapy. She remains active and independent, and her condition demonstrates how maintaining biological control and functional stability can represent meaningful progress in the management of metastatic cancer.

She has chosen to share her experience not as a claim of cure, but as an example of resilience and measurable disease control while continuing her life and work.